Silverarc Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Silverarc Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23,054	Closed	-$2.62M	–	110
2022 Q4	$2.62M	Buy	23,054 +12,923	+128%	+$1.07M	0.75%	47
2022 Q3	$627K	Sell	10,131 -62,056	-86%	-$4.34M	0.21%	65
2022 Q2	$5.76M	Buy	72,187 +4,745	+7%	+$449K	1.77%	21
2022 Q1	$7.1M	Buy	67,442 +5,742	+9%	+$560K	2.94%	9
2021 Q4	$6.65M	Buy	61,700 +9,231	+18%	+$1.01M	2.69%	12
2021 Q3	$5.75M	Buy	52,469 +2,434	+5%	+$253K	3.25%	6
2021 Q2	$4.68M	Buy	50,035 +1,559	+3%	+$143K	2.09%	14
2021 Q1	$4.46M	Buy	48,476 +18,476	+62%	+$1.56M	2.43%	10
2020 Q4	$2.19M	Buy	+30,000	New	+$2.23M	1.28%	31

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Silverarc Capital Management's HZNP Position: Q1 2023 in Review

Silverarc Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 23,054 shares — an estimated $2.62M sold.

Silverarc Capital Management first reported a position in HZNP in Q4 2020 and held it in 9 quarters. The position peaked at $7.1M in Q1 2022. 552 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Silverarc Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Silverarc Capital Management sold 23,054 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $2.62M.
Silverarc Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 9 quarters.
Silverarc Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.1M in Q1 2022.
552 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Silverarc Capital Management's 13F filing for Q1 2023, filed 15 May 2023.